Issue: Exclusive Online Content, Posted Date: 12/20/2016
Dalton Enters Into Agreement With USAMMDA in Support of US Army’s Drug Development Program
Pharma Services, a privately owned pharmaceutical services provider, recently
announced that it has entered into a contract service agreement with the United
States Army Medical Materiel Development Activity (USAMMDA) in support of the
US Army’s product development program for the treatment of severe or
complicated malaria due to Plasmodium
falciparum. Under the awarded contract with USAMMDA, Dalton
will provide cGMP sterile powder filling, aseptic liquid filling, quality control
release testing and ICH stability services for their anti-malarial drug
remains one of the most important infectious disease threats to service members
deployed to endemic areas and has a long history as the cause of disease and
non-battle injury to military personnel. Despite the use of preventative
measures to reduce the risk of malarial infection, service members continue to
contract this disease due to operational constraints, lack of compliance, and
drug-resistant malarial parasites.
leadership role taken by USAMMDA in the development of this important therapy
for malaria treatment is to be commended, and we are privileged to support this
critical program developing safe and effective anti-malarial drugs for
emergency treatment protocols,” said Peter Pekos, President and CEO of Dalton.
is the Department of Defense's (DoD) advanced development activity for products
designed to protect and preserve the lives of Warfighters. USAMMDA develops new
drugs, vaccines and medical support equipment that enhance readiness, ensures
the provision of the highest quality medical care to the DoD and maximizes
survival of medical casualties on the battlefield.
Chemical Laboratories Inc. o/a Dalton Pharma Services is a Health Canada
approved and FDA registered cGMP contract service provider of integrated
chemistry, drug development and manufacturing services to the pharmaceutical
and biotechnology industries. We bring 30 years of experience to our client's
projects and emphasize quality, speed and flexibility. Dalton can accelerate
your drug discovery and development program by integrating process development,
cGMP API manufacturing and sterile or solid finished dose manufacturing all at
a single location. For our full range of in-house services including cGMP sterile fill/finish services,visit www.dalton.com.
CMO 2016 Leadership Awards in the categories of Quality, Reliability,
Capabilities, Expertise and Compatibility including “On-Time Delivery” and
“Right First Time” from Life Science Leader reflect our ongoing commitment to
our clients, peers and the business community.
Canada M3J 2S3
This record has been viewed 852 times.